Abstract
BACKGROUND: Leukotriene receptor antagonists have been shown to protect against bronchoconstriction induced by antigens, exercise, and cold air. There are relatively few clinical studies reported in patients with asthma. The present study is the first clinical evaluation of pranlukast (SB 205312, ONO-1078) outside Japan in patients with asthma. METHODS: A randomised, double blind, placebo controlled, parallel group, multicentre four week study of the safety and tolerability of oral pranlukast, 225 or 337.5 mg twice daily, was performed in patients with mild to moderate asthma. Preliminary efficacy data were obtained; the main efficacy variables evaluated were forced expiratory volume in one second (FEV1) and morning domiciliary (home) peak expiratory flow rates (PEFR). Clinic PEFR and daytime and night-time asthma symptom scores were also recorded. RESULTS: Compared with the placebo group the improvement in morning home PEFR was statistically significant at all time points for patients receiving pranlukast 337.5 mg twice daily and at weeks 1 and 2 for those treated with pranlukast in a dose of 225 mg twice daily. Mean morning home PEFR increased by 10.8 to 18.61/min (95% CI 0.2 to 29.3 l/min) in patients treated with pranlukast compared with a slight deterioration in those given placebo. FEV1 significantly increased within one hour after the first dose of pranlukast compared with baseline and this increase was maintained for eight hours. Improvements in trough FEV1-that is, at the end of the dosing interval- were statistically significant for the group treated with pranlukast 225 mg twice daily compared with placebo at week 4. Mean increases in FEV1 ranged from 210 ml to 340 ml (95% CI 60 to 500 ml) at trough in the pranlukast group. Patients treated with pranlukast also showed improvements in summary symptom and night-time asthma scores. Pranlukast was well tolerated, and no drug related changes in haematological and biochemical variables were observed. CONCLUSIONS: Pranlukast, an oral leukotriene receptor antagonist, is well tolerated and is effective for the treatment of asthma. It increased FEV1 within one hour of dosing, improved patient summary symptom and night-time asthma scores, and reduced the use of rescue bronchodilators, thus providing further evidence of a role for leukotrienes in the pathogenesis of asthma.
Full Text
The Full Text of this article is available as a PDF (123.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cloud M. L., Enas G. C., Kemp J., Platts-Mills T., Altman L. C., Townley R., Tinkelman D., King T., Jr, Middleton E., Sheffer A. L. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989 Nov;140(5):1336–1339. doi: 10.1164/ajrccm/140.5.1336. [DOI] [PubMed] [Google Scholar]
- Fujimura M., Sakamoto S., Kamio Y., Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 1993 Feb;87(2):133–138. doi: 10.1016/0954-6111(93)90141-l. [DOI] [PubMed] [Google Scholar]
- Israel E., Rubin P., Kemp J. P., Grossman J., Pierson W., Siegel S. C., Tinkelman D., Murray J. J., Busse W., Segal A. T. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993 Dec 1;119(11):1059–1066. doi: 10.7326/0003-4819-119-11-199312010-00001. [DOI] [PubMed] [Google Scholar]
- Manning P. J., Watson R. M., Margolskee D. J., Williams V. C., Schwartz J. I., O'Byrne P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. doi: 10.1056/NEJM199012203232504. [DOI] [PubMed] [Google Scholar]
- Murphy R. C., Hammarström S., Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4275–4279. doi: 10.1073/pnas.76.9.4275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakagawa N., Obata T., Kobayashi T., Okada Y., Nambu F., Terawaki T., Aishita H. In vivo pharmacologic profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist. Jpn J Pharmacol. 1992 Nov;60(3):217–225. doi: 10.1254/jjp.60.217. [DOI] [PubMed] [Google Scholar]
- Rasmussen J. B., Margolskee D. J., Eriksson L. O., Williams V. C., Andersson K. E. Leukotriene (LT) D4 is involved in antigen-induced asthma: a study with the LTD4 receptor antagonist, MK-571. Ann N Y Acad Sci. 1991;629:436–436. doi: 10.1111/j.1749-6632.1991.tb38010.x. [DOI] [PubMed] [Google Scholar]
- Spector S. L., Smith L. J., Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994 Sep;150(3):618–623. doi: 10.1164/ajrccm.150.3.8087328. [DOI] [PubMed] [Google Scholar]
- Taki F., Suzuki R., Torii K., Matsumoto S., Taniguchi H., Takagi K. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittelforschung. 1994 Mar;44(3):330–333. [PubMed] [Google Scholar]
- Taniguchi Y., Tamura G., Honma M., Aizawa T., Maruyama N., Shirato K., Takishima T. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol. 1993 Oct;92(4):507–512. doi: 10.1016/0091-6749(93)90074-p. [DOI] [PubMed] [Google Scholar]
- Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]
- Yamaguchi T., Kohrogi H., Honda I., Kawano O., Sugimoto M., Araki S., Ando M. A novel leukotriene antagonist, ONO-1078, inhibits and reverses human bronchial contraction induced by leukotrienes C4 and D4 and antigen in vitro. Am Rev Respir Dis. 1992 Oct;146(4):923–929. doi: 10.1164/ajrccm/146.4.923. [DOI] [PubMed] [Google Scholar]